This study examined whether the sensory neuropeptide calcitonin gene-related peptide (CGRP) inhibits release of chemokines by dermal microvascular endothelial cells. Dermal blood vessels are associated with nerves containing CGRP, suggesting that CGRP-containing nerves may regulate cutaneous inflammation through effects on vessels. We examined CGRP effects on stimulated chemokine production by a human dermal microvascular endothelial cell line (HMEC-1) and primary human dermal microvascular endothelial cells (pHDMECs). HMEC-1 cells and pHDMECs expressed mRNA for components of the CGRP and adrenomedullin receptors and CGRP inhibited LPS-induced production of the chemokines CXCL8, CCL2, and CXCL1 by both HMEC-1 cells and pHDMECs. The receptor activity-modifying protein (RAMP)1/calcitonin receptor-like receptor (CL)-specific antagonists CGRP 8-37 and BIBN4096BS, blocked this effect of CGRP in a dose-dependent manner. CGRP prevented LPS-induced IjBa degradation and NF-jB binding to the promoters of CXCL1, CXCL8 and CCL2 in HMEC-1 cells and Bay 11-7085, an inhibitor of NF-jB activation, suppressed LPS-induced production of CXCL1, CXCL8 and CCL2. Thus, the NF-jB pathway appears to be involved in CGRP-mediated suppression of chemokine production. Accordingly, CGRP treatment of LPS-stimulated HMEC-1 cells inhibited their ability to chemoattract human neutrophils and mononuclear cells. Elucidation of this pathway may suggest new avenues for therapeutic manipulation of cutaneous inflammation.
a b s t r a c t
This study examined whether the sensory neuropeptide calcitonin gene-related peptide (CGRP) inhibits release of chemokines by dermal microvascular endothelial cells. Dermal blood vessels are associated with nerves containing CGRP, suggesting that CGRP-containing nerves may regulate cutaneous inflammation through effects on vessels. We examined CGRP effects on stimulated chemokine production by a human dermal microvascular endothelial cell line (HMEC-1) and primary human dermal microvascular endothelial cells (pHDMECs). HMEC-1 cells and pHDMECs expressed mRNA for components of the CGRP and adrenomedullin receptors and CGRP inhibited LPS-induced production of the chemokines CXCL8, CCL2, and CXCL1 by both HMEC-1 cells and pHDMECs. The receptor activity-modifying protein (RAMP)1/calcitonin receptor-like receptor (CL)-specific antagonists CGRP 8-37 and BIBN4096BS, blocked this effect of CGRP in a dose-dependent manner. CGRP prevented LPS-induced IjBa degradation and NF-jB binding to the promoters of CXCL1, CXCL8 and CCL2 in HMEC-1 cells and Bay 11-7085, an inhibitor of NF-jB activation, suppressed LPS-induced production of CXCL1, CXCL8 and CCL2. Thus, the NF-jB pathway appears to be involved in CGRP-mediated suppression of chemokine production. Accordingly, CGRP treatment of LPS-stimulated HMEC-1 cells inhibited their ability to chemoattract human neutrophils and mononuclear cells. Elucidation of this pathway may suggest new avenues for therapeutic manipulation of cutaneous inflammation.
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Introduction
Dermal microvascular endothelial cells contribute to cutaneous inflammation through many mechanisms. Amongst these is the capacity to release chemokines that play a role in recruiting inflammatory cells (Goebeler et al., 1997; Bender et al., 2008) . Hence, as endothelial-derived chemokines play a crucial role in inflammation and disease, regulation of their expression presents an approach to the management of inflammatory skin disease.
Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide generated by tissue-specific alternative processing of the calcitonin gene (Amara et al., 1982; Rosenfeld et al., 1983) . It is widely distributed in organs of the immune system as well as the central and peripheral nervous systems and is generally co-expressed with either somatostatin or substance P in sensory neurons (Brain and Williams, 1988; Zaidi et al., 1990; Brain, 1997) . CGRP attenuates various immune responses including inhibition of the production of Th1-type cytokines, attenuation of interleukin (IL)-1b induced reactive oxygen species in alveolar epithelial type II cells (Li et al., 2006) , inhibition of mitogen-stimulated T lymphocyte and thymocyte proliferation (Umeda et al., 1988; Bulloch et al., 1991 Bulloch et al., , 1998 , and suppression of the production of IL-2 and other cytokines by CD4 + Th1 cell clones (Wang et al., 1992) . CGRP can also function as a mediator of inflammation; it is a potent endogenous vasodilator and is involved in the accumulation of inflammatory cells in areas of inflammation (Li and Wang, 2006; Hartung and Toyka, 1989; Merhi et al., 1998; Benrath et al., 1995) . In accord with these observations, CGRP enhances adhesion of neutrophils to endothelium in vitro (Zimmerman et al., 1992) . However, in other experiments CGRP was found to inhibit inflammation not associated with adaptive immunity. For example, CGRP inhibits edema-promoting actions of inflammatory mediators (histamine, leukotrine B4, 5-hydroxytryptamine) in vivo in the hamster cheek pouch, human skin, and rat paw (Raud et al., 1991) . Additionally, systemic treatment of mice with CGRP reduced blood neutrophilia induced by systemic administration of LPS and also protected against a lethal dose of LPS (Gomes et al., 2005) . With regard to adaptive immunity, CGRP-containing epidermal nerves are intimately associated with Langerhans cells (LC) in the skin and CGRP inhibits antigen presentation by LC in vitro (Hosoi et al., 1993) . After intradermal administration, CGRP inhibits the 0889-1591/$ -see front matter Ó 2011 Elsevier Inc. All rights reserved. doi:10.1016/j.bbi.2011.02.007
